7TEU

Crystal structure of JAK2 JH1 with type II inhibitor YLIU-04-105-1

Summary for 7TEU

Entry DOI	10.2210/pdb7teu/pdb
Descriptor	Tyrosine-protein kinase JAK2, 3-{(4S)-2-[(cyclopropanecarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}-N-{3-[(4-ethylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl}-4-methylbenzamide, GLYCEROL, ... (4 entities in total)
Functional Keywords	jak2, tyrosine kinase, inhibitor, cytokine signaling, transferase, transferase-inhibitor complex, transferase/inhibitor
Biological source	Homo sapiens (human)
Total number of polymer chains	1
Total formula weight	37788.09
Authors	Hubbard, S.R. (deposition date: 2022-01-05, release date: 2023-06-21, Last modification date: 2023-10-25)
Primary citation	Arwood, M.L.,Liu, Y.,Harkins, S.K.,Weinstock, D.M.,Yang, L.,Stevenson, K.E.,Plana, O.D.,Dong, J.,Cirka, H.,Jones, K.L.,Virtanen, A.T.,Gupta, D.G.,Ceas, A.,Lawney, B.,Yoda, A.,Leahy, C.,Hao, M.,He, Z.,Choi, H.G.,Wang, Y.,Silvennoinen, O.,Hubbard, S.R.,Zhang, T.,Gray, N.S.,Li, L.S. New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. Cell Chem Biol, 30:618-, 2023 Cited by PubMed: 37290440 DOI: 10.1016/j.chembiol.2023.05.007 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.45 Å)

Structure validation